CC Chemokine Receptor 4 (CCR4) in Human Allergen-induced Late Nasal Responses
Overview
Authors
Affiliations
Background: CC Chemokine receptor 4 (CCR4) is preferentially expressed on Th2 lymphocytes. CCR4-mediated inflammation may be important in the pathology of allergic rhinitis. Disruption of CCR4 - ligand interaction may abrogate allergen-induced inflammation.
Methods: Sixteen allergic rhinitics and six nonatopic individuals underwent both allergen and control (diluent) nasal challenges. Symptom scores and peak nasal inspiratory flow were recorded. Nasal biopsies were taken at 8 h post challenge. Sections were immunostained and examined by light or dual immunofluorescence microscopy for eosinophils, T-lymphocytes, CCR4(+)CD3(+) and CXCR3(+)CD3(+) cells and examined by in situ hybridization for CCR4, IL-4 and IFN-gamma mRNA(+) cells. Peripheral blood mononuclear cells were obtained from peripheral blood of nine normal donors and the CCR4(+)CD4(+) cells assessed for actin polymerization in response to the CCR4 ligand macrophage-derived chemokine (MDC/CCL22) and the influence of a CCR4 antagonist tested.
Results: Allergic rhinitics had increased early and late phase symptoms after allergen challenge compared to diluent; nonatopics did not respond to either challenge. Eosinophils, but not total numbers of CD3(+) T cells, were increased in rhinitics following allergen challenge. In rhinitics, there was an increase in CCR4(+)CD3(+) protein-positive cells relative to CXCR3(+)CD3(+) cells; CCR4 mRNA+ cells were increased and IL-4 increased to a greater extent than IFN-gamma. CCR4(+)CD4(+) T cells responded to MDC in vitro, and this response was inhibited by the selective CCR4 antagonist.
Conclusion: Lymphocyte CCR4 expression is closely associated with induction of human allergen-induced late nasal responses. Blocking CCR4-ligand interaction may provide a novel therapeutic approach in allergic disease.
Khanzadeh M, Foroughi Nematollahi S, Shavakhi M, Ghaedi A, Mallahi A, Bazrgar A Indian J Otolaryngol Head Neck Surg. 2024; 76(1):1389-1397.
PMID: 38440632 PMC: 10909046. DOI: 10.1007/s12070-023-04148-8.
Reithofer M, Boell S, Kitzmueller C, Horak F, Bohle B, Jahn-Schmid B Heliyon. 2023; 9(11):e21878.
PMID: 38034768 PMC: 10685201. DOI: 10.1016/j.heliyon.2023.e21878.
CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy.
Bogacka J, Pawlik K, Ciapala K, Ciechanowska A, Mika J Int J Mol Sci. 2022; 23(24).
PMID: 36555280 PMC: 9779674. DOI: 10.3390/ijms232415638.
Li Z, Yu S, Jiang Y, Fu Y Eur Arch Otorhinolaryngol. 2022; 279(11):5089-5095.
PMID: 35732904 DOI: 10.1007/s00405-022-07485-6.
Alternatively activated macrophages; a double-edged sword in allergic asthma.
Abdelaziz M, Abdelwahab S, Wan J, Cai W, Huixuan W, Jianjun C J Transl Med. 2020; 18(1):58.
PMID: 32024540 PMC: 7003359. DOI: 10.1186/s12967-020-02251-w.